Please provide your email address to receive an email when new articles are posted on . Five-year all-cause death was higher in patients with undiagnosed HFpEF vs. those who received a ...
Phenotyping patients can help to identify potential heart failure with preserved ejection fraction (HFpEF) as well as improve patient outcomes.
Many people with heart failure (HF) with preserved ejection fraction (HFpEF) may be undiagnosed. These patients face a higher mortality risk and would likely benefit from additional clinical attention ...
A new analysis, designed to shed light on the benefits of SGLT2 inhibition in patients who have heart failure with preserved ejection fraction (HFpEF), shows that dapagliflozin (Farxiga; AstraZeneca) ...
Tirzepatide reduced cardiovascular death or heart failure worsening by 38% in patients with obesity and HFpEF, compared to placebo. The trial showed significant weight loss and improved insulin ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback